Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic LeukemiaKaren Thudium Mueller, Edward Waldron, Stephan A Grupp, et al.Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2026
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALLStephan A Grupp, Shannon L Maude, Susana Rives, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.Pageof 2